I visited my aunt at her retirement home in Baltimore County last night.
A nice enough place; she seems to enjoy the company and accommodations.
We sat and chatted at an end table in a common area otherwise dominated by the sound of Mad Money's Jim Cramer blasting through the speaker of the home's old 19" Zenith.
Funny, I thought... I could barely see Cramer from where I was sitting, but he made for great background noise.
Now the last time I brought up Jim Cramer in the pages of Wealth Daily was April 2009. That's when we were urging readers like you to jump on what would turn into 300% gains on Dendreon calls in just six days...
(The same $6 stock Cramer pleaded with his viewers to sell. As he put it, "This is the one where I got in trouble... I do not like Dendreon. I think it is up too much on a spike. Sell. Sell. Sell.")
I know, I know. Regardless of how you feel about Cramer, he does eventually come around now and then... including two weeks ago, when he finally asserted a buy position on DNDN.
Now let's dig a little deeper into this Dendreon trade...
Here's what our call options did on April 14, 2009 — the day Dendreon blew up (immediately after Cramer's "sell" recommendations.)
Now, what if I told you we could do even better a year out?
Well, if you were following in 2007, you'd be up more than 570% on the stock, and thousands of percentage points on the call options, as the underlying stock was just halted at $45. Take a look:
And if we're right again... it could open big this morning after yesterday's $15 run after the halt, handing explosive profits to any one that took our advice.
In fact, I've got another stock — the same one we mentioned in the White Oak FDA report — that just handed readers a 53% gain in six trading days. And FDA approval isn't even slated until tomorrow.
Back to Dendreon...
You see, unlike traditional vaccines that prevent disease, the company's Provenge medicine treats disease by stimulating the body's own immune system, according to Reuters.
And considering that prostate cancer is the most common cancer diagnosed in American males, what man suffering from prostate problems is going to turn down a drug when his doctor tells him, "You'll have no side effects with this drug, and it will probably extend your life"?
That reality could turn Provenge into a $200 million product — with the possibility of a $1 billion blockbuster hit if it's expanded to men with earlier stages of the disease.
And thanks to the FDA, some very patient investors, and many brave prostate cancer survivors, patience is paying off many times over.
The agency says it cleared marketing of Dendreon's Provenge, which is intended to treat prostate cancer that has spread elsewhere in the body and is not responding to hormone therapy.
Can you smell that, dear reader? That's the smell of early retirement from one stock and its options.
But here's the kicker: That other aforementioned stock that just handed Options Trading Pit readers a 53% on half the position doesn't face the FDA until tomorrow — and there's still time to buy it.
In fact, there's still time to buy the other two FDA positions we're in and the dozens still coming from Options Trading Pit.
Staying Ahead of the Curve,
Ian L. Cooper